Newly HK-listed 3SBio buys ex-China rights to Apexigen MAB candidate

Recently listed in Hong Kong 3SBio said it has bought the ex-China rights to Apexigen's anti-TNF monoclonal antibody technology, adding to mainland rights held since 2006. The candidate, SSS07, has demonstrated higher potency than the best-known available TNF inhibitors, including adalimumab and infliximab, in preclinical testing, according to a press release. In March 2015, 3SBio initiated a dose-escalating Phase I trial for SSS07 in China (NCT02460393), the release said, adding that a Phase Ib trial is also scheduled to start in early 2016 using multiple doses in healthy individuals. Earlier this month, 3SBio returned to the capital markets two years after delisting from the Nasdaq, marking a new bright spot for unlisted Asian biotechs to look closer to home for cash. The Shenyang-based company raised approximately $710 million in the Hong Kong initial public offering, according to a press release. Release